Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer

被引：3

作者：

Lin, Feizhi ^{[1
]}

Chen, Yongming ^{[1
]}

Huang, Bowen ^{[1
]}

Ruan, Shenghang ^{[1
]}

Lin, Jun ^{[1
]}

Chen, Zewei ^{[1
]}

Huang, Chunyu ^{[1
]}

Zhao, Baiwei ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2024年 / 15卷

关键词：

perioperative treatment; gastric cancer; immunotherapy; neoadjuvant therapy; adjuvant therapy; chemotherapy; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; RANDOMIZED PHASE-II; GASTRIC-CANCER; OPEN-LABEL; DOUBLE-BLIND; PERIOPERATIVE CHEMOTHERAPY; PLUS CHEMOTHERAPY; TRIAL; OXALIPLATIN; GASTRECTOMY;

D O I：

10.3389/fphar.2024.1391562

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Gastric/gastroesophageal junction (G/GEJ) cancer represents a significant global health challenge. Radical surgery remains the cornerstone of treatment for resectable G/GEJ cancer. Supported by robust evidence from multiple clinical studies, therapeutic approaches, including adjuvant chemotherapy or chemoradiation, and perioperative chemotherapy, are generally recommended to reduce the risk of recurrence and enhance long-term survival outcomes post-surgery. In recent years, immune checkpoint inhibitors (ICIs) have altered the landscape of systemic treatment for advanced or metastatic G/GEJ cancer, becoming the standard first-line therapy for specific patients. Consequently, exploring the efficacy of ICIs in the adjuvant or neoadjuvant setting for resectable G/GEJ cancer is worthwhile. This review summarizes the current advances in the application of ICIs for resectable G/GEJ cancer.

引用

页数：13

共 50 条

[31] The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer
Murphy, Adrian G.
Kelly, Ronan J.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (03) : 485 - +
[32] A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors
Dayyani, Farshid
Chao, Joseph
Lee, Fa-Chyi
Taylor, Thomas H.
Neumann, Kristen
Cho, May T.
ONCOLOGIST, 2024, 29 (08): : 721 - +
[33] Immune checkpoint inhibitors in cancer therapy
Eika S.Webb
Peng Liu
Renato Baleeiro
Nicholas R.Lemoine
Ming Yuan
Yaohe Wang
The Journal of Biomedical Research, 2018, 32 (05) : 317 - 326
[34] Immune checkpoint inhibitors in cancer therapy
Webb, Eika S.
Liu, Peng
Baleeiro, Renato
Lemoine, Nicholas R.
Yuan, Ming
Wang, Yaohe
JOURNAL OF BIOMEDICAL RESEARCH, 2018, 32 (05): : 317 - 326
[35] Immune checkpoint inhibitors for cancer treatment
Park, Junsik
Kwon, Minsuk
Shin, Eui-Cheol
ARCHIVES OF PHARMACAL RESEARCH, 2016, 39 (11) : 1577 - 1587
[36] Immune checkpoint inhibitors in lung cancer
Koleczko, S.
Wolf, J.
INTERNIST, 2020, 61 (07): : 676 - 681
[37] Immune Checkpoint Inhibitors in Cancer Therapeutics
不详
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) : 6 - 6
[38] Immune checkpoint inhibitors in cancer immunotherapy
Himmel, Megan E.
Saibil, Samuel D.
Saltman, Alexandra P.
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (24) : E651 - E651
[39] Immune checkpoint inhibitors in penile cancer
Buonerba, Carlo
Scafuri, Luca
Costabile, Ferdinando
D'Ambrosio, Bruno
Gatani, Simona
Verolino, Pasquale
Di Trolio, Rossella
Cosimato, Vincenzo
Verde, Antonio
Di Lorenzo, Giuseppe
FUTURE SCIENCE OA, 2021, 7 (07):
[40] Immune Checkpoint Inhibitors in the Treatment of Cancer
Zam, Wissam
Ali, Lina
CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2022, 17 (02) : 103 - 113

← 1 2 3 4 5 →